Prostate cancer Board decisions

The Board remands the issue of entitlement to service connection for prostate cancer claimed as due to herbicide exposure for further development, specifically directing that efforts be made to verify the Veteran's alleged in-service exposure through the US Army Records Research Center.

The Board remands the claims for service connection for Parkinson's disease, prostate cancer, bilateral choroidal melanoma, malignant melanoma of the back, and a respiratory disability due to outstanding evidence and duty-to-assist errors.

The Board denied the application to readjudicate a previously denied claim of service connection for lumbosacral strain and degenerative arthritis of the spine, as no new and relevant evidence was submitted. The claims for prostate cancer and bladder disability were remanded for further development.

The Board granted service connection for prostate cancer, which is presumptively linked to the Veteran's exposure to herbicide agents during his service at Takhli Royal Thai Air Force Base in Thailand.

The Board granted an initial 40 percent rating for prostate cancer from August 10, 2022, to September 21, 2023, and a 100 percent rating from September 22, 2023, as well as a 100 percent rating for malignant neoplasm of the bones from September 22, 2023.

The Board granted an earlier effective date of August 30, 2022, for the 60 percent rating for prostate cancer and special monthly compensation based on housebound criteria but denied a compensable rating for erectile dysfunction.

The Board granted service connection for tinnitus and denied service connection for kidney disease and prostate cancer. The claims for a left knee condition, right knee condition, ischemic heart disease, and hypertension were remanded.

The Board remands the claim for service connection of prostate cancer to obtain an adequate medical opinion regarding the etiology of the condition, specifically addressing exposure to aqueous film-forming foam (AFFF) during service.

The appeals for a compensable evaluation for umbilical hernia and service connection for prostate cancer have been withdrawn by the Veteran's authorized representative.

The Board granted service connection for monoclonal gammopathy of undetermined significance, prostate cancer, hypertension, a cardiac disability, pubis scar as secondary to prostate cancer, erectile dysfunction as secondary to prostate cancer, and special monthly compensation based on loss of use of a creative organ. The claim for an initial rating in excess of 50 percent for an acquired psychiatric disorder was denied, as were the claims for an initial compensable rating for bilateral hearing loss.

The Board denied service connection for chronic pulmonary embolism, basal cell carcinoma of the left lower extremity, prostate cancer, and COPD as there was no credible evidence linking these conditions to the Veteran's active military service.

The appeal for service connection for left and right lower extremity peripheral neuropathy was dismissed due to the Veteran's withdrawal of his appeal. The other claims were remanded for further development.

The Board granted the appeal, setting the proper effective date for the reduction in the rating for prostate cancer residuals from 100 percent to 60 percent as February 28, 2025.

The Board granted service connection for prostate cancer, finding that the Veteran's condition is due to exposure to contaminants during active duty at a Superfund site.

The Board granted earlier effective dates for the award of service connection for CAD, type II diabetes mellitus, and prostate cancer, as well as initial ratings for CAD, linear left upper chest scar, type II diabetes mellitus, bilateral upper and lower extremity peripheral neuropathy, and erectile dysfunction.

The Board granted service connection for prostate cancer under the PACT Act due to presumed exposure to burn pits during the Veteran's service in Southwest Asia.

The Board denied service connection for prostate cancer due to a lack of evidence supporting the Veteran's claim of herbicide exposure and a direct link between his condition and military service.

The Board remands the issue of entitlement to service connection for the Veteran's cause of death due to inadequate development regarding potential herbicide exposure.

The Board granted service connection for prostate cancer, which was presumed to be caused by the Veteran's in-service herbicide exposure.

The Veteran's service-connected disabilities, including prostate cancer residuals and traumatic brain injury with unspecified depressive disorder, prevented him from securing and following substantially gainful employment prior to September 26, 2014, warranting a TDIU. However, the evidence does not support a rating above 40 percent for his prostate cancer prior to that date.